Results 21 to 30 of about 6,619 (182)

In vitro and in vivo pharmacological profile of OPC-61815, a water-soluble phosphate ester pro-drug of tolvaptan

open access: yesJournal of Pharmacological Sciences, 2022
Tolvaptan is an orally active vasopressin V2 receptor antagonist and used for the treatment of volume overload in some disease as an aquaretic. Tolvaptan sodium phosphate (OPC-61815) is a pro-drug of tolvaptan that was designed to improve water ...
Hiroyuki Fujiki   +9 more
doaj   +1 more source

Intravenous Tolvaptan Sodium Phosphate Can Fail to Improve Fluid Overload Due to Heart Failure in Patients With Chronic Kidney Disease: A Case Report. [PDF]

open access: yesPharmacol Res Perspect
ABSTRACT Tolvaptan is widely used as an adjunct oral diuretic to loop and thiazide diuretics for the management of fluid overload in patients with congestive heart failure. Recently, tolvaptan sodium phosphate (TSP), a water‐soluble prodrug of tolvaptan, was developed for intravenous administration and has demonstrated efficacy and safety in clinical ...
Uno T   +10 more
europepmc   +2 more sources

The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry

open access: yesESC Heart Failure, 2023
Aims The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated.
Ryusuke Nishikawa   +29 more
doaj   +1 more source

Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan

open access: yesESC Heart Failure, 2021
Aims Real‐world data on the use of tolvaptan, an oral selective vasopressin 2 receptor antagonist, for patients with heart failure (HF) are not available in Western countries because tolvaptan is not indicated in the Western countries for volume overload
Takashi Kuragaichi, Yukihito Sato
doaj   +1 more source

Tolvaptan response predictors in acute heart failure patients with congestion [PDF]

open access: yesPharmaceutical Sciences Asia, 2022
Tolvaptan has been used in many countries as an adjunct to diuretic therapy for heart failure. The identification of predictors of response to tolvaptan is essential in developing individual treatment plans, and this study therefore aims to identify ...
Hindun Wilda Risni   +2 more
doaj   +1 more source

The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.

open access: yes, 2022
The baseline demographic and laboratory data of the tolvaptan group and non-tolvaptan group.
Akinari Sekine (4357189)   +8 more
core   +1 more source

Temporal trends in tolvaptan use after revision of national heart failure guidelines in Japan

open access: yesScientific Reports, 2021
Within no definite diuretic protocol for acute heart failure (AHF) patients and its variation in regional clinical guidelines, the latest national guidelines in Japan commends use of tolvaptan in diuretic-resistant patients.
Yusuke Yamazaki   +6 more
doaj   +1 more source

Analysis of dose effect of tolvaptan on polycystic liver disease.

open access: yes, 2022
To assess the dose effect of tolvaptan on the change in annual growth rate of total liver volume (TLV), the original tolvaptan group were stratified by daily dose of tolvaptan, less than 30mg, 60mg, 90mg, and mg. However, we could not find the any trends
Akinari Sekine (4357189)   +8 more
core   +1 more source

Can tolvaptan usage cause cytotoxicity? An in vitro study

open access: yes, 2023
Objectives: Tolvaptan is a nonpeptide V2 (vasopressin) receptor antagonist which is commonly used for treatment of hypernatremia. Besides it is mostly used for rescue strategies of mutant V2 receptors which are responsible for congenital type of ...
TUNÇDEMİR, Beril ERDEM   +1 more
core   +1 more source

Combination of tolvaptan and valsartan improves cardiac and renal functions in doxorubicin-induced heart failure in mice

open access: yesEuropean Journal of Histochemistry, 2022
Heart failure (HF) is often complicated by renal dysfunction. Tolvaptan and valsartan are two well-known agents for the treatment of HF. However, the role of tolvaptan/valsartan combination on HF with renal dysfunction remains unclear.
Fengqin Yan   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy